Aquestive Therapeutics NASDAQ: AQST is preparing for a potential U.S. launch of its needle-free treatment for severe allergic reactions, with an FDA decision expected on March 16, 2027, CEO Dan Barber said at the 2026 Jefferies Global Healthcare Conference.
The company’s lead product candidate, Anaphylm, is a sublingual film containing dibutepinephrine. If approved, it would be indicated for severe allergic reactions, including anaphylaxis. Barber said Aquestive plans to launch the product on its own in the U.S. and is discussing potential partnerships outside the country.
FDA Review and Launch Funding
Aquestive originally submitted its application for Anaphylm in March 2025 and received a complete response letter from the FDA in January 2026. Barber said the letter concerned packaging and administration instructions, and the company subsequently resubmitted the application.
The FDA also asked the company to examine what happens when the film is placed on top of the tongue rather than underneath it, Barber said. He said drug exposure was lower in that scenario, but the observed blood-pressure response remained strong.
At the end of the last quarter, Aquestive had $90 million in cash, Barber said. The company also has $75 million committed by RTW upon approval for the sales launch and access to $20 million under its Oaktree vehicle. Together, he said, those resources would provide just under $200 million for a launch.
Clinical Data and Questions
Barber presented company data showing a 12-minute time to peak absorption for Anaphylm, compared with 20 minutes for an auto-injector. He also said the film produced a higher and more extensive change in blood pressure than EpiPen in the data he presented. He described the product’s portability and resistance to temperature and water as advantages over auto-injectors.
In a preference exercise involving 53 people, 51 preferred the film to a nasal spray, one preferred the spray and one expressed no preference, Barber said.
During the question-and-answer session, Paul Deutsch, an analyst at Ascenta Capital, asked whether the film’s blood-pressure effects could be excessive or concerning to physicians. Barber said the FDA had put in writing that it saw no greater clinical cardiovascular risk with Anaphylm than with existing auto-injectors. He also said the company’s healthy-volunteer adverse-event data had not raised concerns.
Asked about additional clinical endpoints, Barber said he expected the company’s post-marketing commitments to the FDA to be based on real-world evidence, beginning after approval. He also described the company’s explanation for differences in blood-pressure response as a theory, saying it did not yet know the exact rationale.
Market Plans and Pipeline
Barber estimated that 30 million to 40 million Americans are at risk of a severe allergic reaction, while approximately 5 million to 5.5 million prescriptions are written annually. Aquestive expects prescriptions to reach 7.5 million by 2029 and, using existing branded-product pricing, estimates the U.S. market could be worth roughly $2 billion by then. The company has not set a price for Anaphylm, he said.
Aquestive plans to deploy about 75 sales representatives, focusing on allergists and high-prescribing pediatricians and ear, nose and throat physicians. Barber said the company is also engaging insurers before approval, including discussions about potential costs associated with urgent-care and emergency-room visits.
Outside the U.S., the company plans to file for Anaphylm in Canada before year-end, in Europe in the first quarter and in the U.K. in the second quarter, Barber said.
Aquestive also recently announced a relationship with Eton Pharmaceuticals for Libervant in the U.S. Barber said Libervant is tentatively approved and awaiting the expiration of orphan drug exclusivity. Another candidate, AQST-108, is a topical epinephrine gel for atopic dermatitis in Phase 1 development.
About Aquestive Therapeutics (NASDAQ:AQST)
Aquestive Therapeutics is a pharmaceutical company that develops medicines and drug-delivery technologies, with a focus on treatments for central nervous system disorders and severe allergic reactions. Its PharmFilm technology enables medicines to be delivered in dissolvable oral films. The company's products and product portfolio have included Sympazan, a clobazam oral film for seizures associated with Lennox-Gastaut syndrome, and Libervant, a diazepam buccal film for seizure clusters. Aquestive has also developed film-based medicines with commercial partners, including formulations of Suboxone and Zuplenz.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aquestive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aquestive Therapeutics wasn't on the list.
While Aquestive Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.